A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
about
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Study of IMO-2125 in Combina ...... tory Melanoma (ILLUMINATE-301)
@en
type
label
A Study of IMO-2125 in Combina ...... tory Melanoma (ILLUMINATE-301)
@en
prefLabel
A Study of IMO-2125 in Combina ...... tory Melanoma (ILLUMINATE-301)
@en
P17
P6153
P1050
P1476
A Randomized Phase 3 Compariso ...... tory Melanoma (ILLUMINATE-301)
@en
P1813
ILLUMINATE-301
@en
P3098
NCT03445533
P580
2018-05-30T00:00:00Z
P582
2021-11-01T00:00:00Z